Targeting Triple-Negative Breast Cancer

Targeting Triple-Negative Breast Cancer

Molecular and Immunologic Approaches

Not a member of My prIME? Join now for instant access.

Meeting Overview

Get the latest updates in triple-negative breast cancer at this interactive satellite symposium. A variety of topics will be discussed, including an overview of the molecular and clinical diversity of triple-negative breast cancer and the latest molecular, genetic, and immune-therapeutic targets for treatment. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

Date and Location

Monday, June 4, 2018
6.00 AM – 8.00 AM

Sheraton Ballrooms 1 & 2
Sheraton Chicago
301 East North Water Street
Chicago, Illinois 60611



Monday, June 4, 2018
6.00 AM – 8.00 AM



Chicago, Illinois, United States



1.75 AMA PRA Category 1 Credits™

Monday, June 4

6.00 AM Registration and breakfast
6.15 AM Welcome, introductions, and TNBC quiz
Hope S. Rugo, MD, FACP
6.25 AM Triple-negative breast cancer – Time to slice and dice?
Carsten Denkert, MD
6.40 AM Questions and faculty discussion
6.45 AM Smart weapons in the treatment of triple-negative breast cancer
Hope S. Rugo, MD, FACP
7.00 AM Questions and faculty discussion
7.05 AM Exploiting abnormalities in DNA repair
Nicholas Turner, MD, PhD
7.20 AM Questions and faculty discussion
7.25 AM Can we make immunotherapy a success in breast cancer?
Sylvia Adams, MD, MS
7.40 AM Questions and faculty discussion
7.45 AM Clinical practice update
Hope S. Rugo, MD, FACP
7.58 AM prIME Points™
Hope S. Rugo, MD, FACP
8.00 AM Adjourn


  • Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, United States
  • Faculty

  • Sylvia Adams, MD, MSNew York University School of Medicine
    Perlmutter Cancer Center
    New York, New York, United States
  • Carsten Denkert, MDCharité University Hospital
    Berlin, Germany
  • Nicholas Turner, MD, PhDRoyal Marsden Hospital
    London, United Kingdom

This educational activity is designed to meet the needs of medical oncologists, surgical and radiation oncologists, nurses, nurse practitioners, physician assistants, and other healthcare providers who treat and manage patients with breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess the molecular characteristics of triple-negative breast cancer and the clinical features of this diverse set of conditions
  • Evaluate the results of recent clinical trials with novel targeted treatment approaches in triple-negative breast cancer
  • Identify the relevance of PARPi in the treatment of patients with BRCA-mutated and BRCA-like triple-negative breast cancer
  • Describe the potential role of immunotherapy in the management of triple-negative breast cancer

This educational activity is supported by grants from Merck and Co, Inc. and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Targeting Triple-Negative Breast Cancer - prIME Oncology

prIME Oncology designates this live activity a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.